Encompass Health Corporation (EHC) P/E Ratio History
Historical price-to-earnings valuation from 1990 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 2, 2026, Encompass Health Corporation (EHC) trades at a price-to-earnings ratio of 19.4x, with a stock price of $107.88 and trailing twelve-month earnings per share of $5.29.
The current P/E is roughly in line with its 5-year average of 19.6x. Over the past five years, EHC's P/E has ranged from a low of 12.6x to a high of 24.0x, placing the current valuation at the 40th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, EHC trades at a 18% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
The PEG ratio of 1.36 (P/E divided by 24% EPS growth) suggests a fair valuation relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, EHC trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our EHC DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Post-acute and senior care peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
ENSGThe Ensign Group, Inc. | $12B | 36.7 | 2.66 | +14% |
EHCEncompass Health Corporation | $11B | 19.4 | 1.36 | +24%Best |
NHCNational HealthCare Corporation | $3B | 21.3 | 0.93Best | +17% |
SEMSelect Medical Holdings Corporation | $2B | 12.9Lowest | - | -30% |
PNTGThe Pennant Group, Inc. | $1B | 40.1 | 3.99 | +18% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $127.02 | $5.29 | 24.0x | +10% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $122.63 | $5.11 | 24.0x | +10% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $101.28 | $4.84 | 20.9x | -4% |
| FY2024 Q4 | $92.35 | $4.46 | 20.7x | -5% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $96.64 | $4.14 | 23.3x | +7% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $85.79 | $3.92 | 21.9x | +0% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $82.58 | $3.70 | 22.3x | +2% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $66.72 | $3.47 | 19.2x | -12% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $67.16 | $3.49 | 19.2x | -12% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $67.71 | $3.10 | 21.8x | +0% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $54.10 | $2.69 | 20.1x | -8% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $59.81 | $2.69 | 22.2x | +2% |
Average P/E for displayed period: 21.8x
See EHC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EHC Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare EHC vs AGIO
See how EHC stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is EHC stock overvalued or undervalued?
EHC trades at 19.4x P/E, near its 5-year average of 19.6x. The 40th percentile ranking places valuation within normal historical bounds.
How does EHC's valuation compare to peers?
Encompass Health Corporation P/E of 19.4x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is EHC's PEG ratio?
EHC PEG ratio is 1.36. Between 1-2 suggests valuation aligns with growth. Historical P/E data spans 1990-2025.